Skip to main content

UBS Biotech Equity Fund

UBS Biotech Equity Fund is an equity fund managed by UBS in the Industri – Bioteknologi category.

About this fund

UBS Biotech Equity Fund sits in the Industri – Bioteknologi peer group, where UBS is the manager.

The fund: 30 years of track record, running since 1996 (share classes may be younger).

It ranks 2 out of 4 in its peer group on return so far this year measured in NOK as of 13.11.2026.

It is run by a team of 3.

The manager states a volatility of 21.2% for the fund.

The reference index is MSCI US Investable Market Biotechnology 10/40 Index (r).

Manager
UBS
Category
Industri – Bioteknologi
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
LU0069152568
Inception
1996-10-15
Benchmark
MSCI US Investable Market Biotechnology 10/40 Index (r)
AUM
502 m USD
Returns
YTD 19.7% · 1Y 25.6% · 3Y 17.4% · 5Y 10.0%

Portfolio managers

Actively managedEquityGlobalHealth care
YTD Return · NOK
+19,7 %from NAV
Calculated NOK return from USD · A (USD) (NOK Calculated)
Last NAV 1 119,55 USD · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+19,7 %
YTD
+25,6 %
1y
+17,4 %
3y, annualised
+10,0 %
5y, annualised
+11,1 %
10y, annualised
Fund size
502,0 mill. USD
Total fund AUM
Management fee
1,63 %
Annual · class A
Ongoing charge
2,11 %
Annual · class A
Performance fee
None
Stated by the manager
Annual cost on platforms
1,57 %–1,59 %
Class A · 3 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Oct 1996
ISIN LU0069152568
BenchmarkMSCI US Investable Market Biotechnology 10/40 Index (r)
Fund website
Risk
Volatility (stated by the manager)21,2 %
Sharpe Ratio0,65
Beta1,09
About the fund
The fund

UBS Biotech Equity Fund has a track record back to 1996. The management company is UBS Asset Management, the asset management division of the listed Swiss banking group UBS Group, headquartered in Zürich. UBS completed its acquisition of Credit Suisse in 2023.

Investment philosophy

The managers state that they favour innovative small and mid-sized companies, especially those with platform technologies that can address multiple disease targets.

The managers

Matthew Konosky and Sarah Schram, both in Chicago, are listed on the fund. Konosky joined UBS in 2006, has managed the fund since 2017 and was previously a healthcare analyst at Sanford C. Bernstein. Schram is a biotechnology analyst with a PhD in neuroscience and has been a named co-manager since 2025, after working as a biotechnology analyst at William Blair. Charlotte Harris in London is also listed, and Pascal Mercier in Zürich was a named manager from 2025 to 2026. They are part of UBS's health care and biotech team, which draws on the healthcare analysts in the US intrinsic value equity team and also manages UBS Sustainable Health Transformation Equity Fund.

The portfolio

The portfolio is concentrated at the top, and the fund has fluctuated less than comparable funds. Steady positions include Vertex Pharmaceuticals, AbbVie, Amgen, Gilead Sciences, Ionis Pharmaceuticals, Insmed, Roivant Sciences and Guardant Health.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

Portfolio managers

CH
Portfolio Manager
MA
Portfolio Manager
On the fund since Oct 1, 2017
SA
Portfolio Manager
On the fund since May 28, 2025

Position in the peer group

Industry Biotechnology Equities · 6 funds in the peer group. The number ranked and the date are stated per period. 3 of them converted to NOK.

2 of 4 funds ranked on a calculated return

#2/ 4Year to date
+19.70% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#1/ 41 year
+25.96% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#3/ 43 years (ann.)
+17.42% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#3/ 45 years (ann.)
+9.96% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

1 year

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data